

Human Absorption, Distribution, Metabolism and Excretion Studies - Origins, Innovations and Importance

Matthew A. Cerny, Douglas K. Spracklin, and R. Scott Obach

Pharmacokinetics, Dynamics, and Metabolism, Pfizer, Inc., Groton, Connecticut

Drug Metabolism and Disposition – DMD-MR-2022-001006

References used to compile Figure 1.

1973

Hucker HB, Stauffer SC, White SD, Rhodes RE, Arison BH, Umbenhauer ER, Bower RJ, and McMahon FG (1973) Physiologic disposition and metabolic fate of a new anti-inflammatory agent, cis-5-fluoro-2-methyl-1-(p-(methylsulfinyl)-benzylidenyl)-indene-3-acetic acid in the rat, dog, rhesus monkey, and man. *Drug Metab Dispos* **1**:721-736.

LePage GA, Khaliq A, and Gottlieb JA (1973) Studies of 9-beta-D-arabinofuranosyladenine in man. *Drug Metab Dispos* **1**:756-759.

Loo TL, Lu K, and Gottlieb JA (1973) Disposition and metabolism of thiopurines. II. Arabinosyl-6-mercaptopurine and ribosyl-6-mercaptopurine. *Drug Metab Dispos* **1**:645-652.

Mitoma C (1973) Metabolic disposition of thiamine tetrahydrofurfuryl disulfide in dog and man. *Drug Metab Dispos* **1**:698-703.

Sisenwine SF, Kimmel HB, Liu AL, Segaloff A, and Ruelius HW (1973) Metabolic disposition of 18-homoestriol in the rat, dog, and man. *Drug Metab Dispos* **1**:537-542

1974

Lesser JM, Israili ZH, Davis DC, and Dayton PG (1974) Metabolism and disposition of hydralazine-14C in man and dog. *Drug Metab Dispos* **2**:351-360.

Vickers S, Stuart EK, Bianchine JR, Hucker HB, Jaffe ME, Rhodes RE, and Vandenhevel WJ (1974) Metabolism of carbidopa (1-(-)-alpha-hydrazino-3,4-dihydroxy-alpha-methylhydrocinnamic acid monohydrate), an aromatic amino acid decarboxylase inhibitor, in the rat, rhesus monkey, and man. *Drug Metab Dispos* **2**:9-22.

1975

Allen JG, East PB, Francis RJ, and Haigh JL (1975) Metabolism of debrisoquine sulfate. Identification of some urinary metabolites in rat and man. *Drug Metab Dispos* **3**:332-337.

Alton KB, Grimes RM, Shaw C, Patrick JE, and McGuire JL (1975) Biotransformation of a 1,5-benzodiazepine, triflubazam, by man. *Drug Metab Dispos* **3**:352-360.

Hintze KL, Wold JS, and Fischer LJ (1975) Disposition of cyproheptadine in rats, mice, and humans and identification of a stable epoxide metabolite. *Drug Metab Dispos* **3**:1-9.

- Karim A, Hribar J, Aksamit W, Doherty M, and Chinn LJ (1975) Spironolactone metabolism in man studied by gas chromatography-mass spectrometry. *Drug Metab Dispos* **3**:467-478.
- Murphy PJ, Williams TL, McMahon RE, Crabtree RE, and Ridolfo AS (1975) Metabolism of propionyl erythromycin lauryl sulfate. II. Fate of the lauryl sulfate moiety in the rat and man. *Drug Metab Dispos* **3**:164-170.
- Porter CC, Arison BH, Gruber VF, Titus DC, and Vandenheuvel WJ (1975) Human metabolism of cyproheptadine. *Drug Metab Dispos* **3**:189-197.
- Pottier J, Busigny M, and Raynaud JP (1975) Pharmacokinetic study of a peripheral analgesic, floctafenin, in man, mouse, rat, and dog. *Drug Metab Dispos* **3**:133-147.
- Sisenwine SF, Kimmel HB, Liu AL, and Ruelius HW (1975) Excretion and stereoselective biotransformations of dl-, d- and l-norgestrel in women. *Drug Metab Dispos* **3**:180-188.
- Sumner DD, Dayton PG, Cucinell SA, and Plostnieks J (1975) Metabolism of tolmetin in rat, monkey, and man. *Drug Metab Dispos* **3**:283-286.
- Tang BK, Inaba T, and Kalow W (1975) N-hydroxyamobarbital: the second major metabolite of amobarbital in man. *Drug Metab Dispos* **3**:479-486.
- Tocco DJ, Breault GO, Zacchei AG, Steelman SL, and Perrier CV (1975a) Physiological disposition and metabolism of 5-(2',4'-difluorophenyl)salicylic acid, a new salicylate. *Drug Metab Dispos* **3**:453-466.
- Tocco DJ, Duncan AE, Delauna FA, Hucker HB, Gruber VF, and Vandenheuvel WJ (1975b) Physiological disposition and metabolism of timolol in man and laboratory animals. *Drug Metab Dispos* **3**:361-370.

1976

- Shargel L and Dorrbecker SA (1976) Physiological disposition and metabolism of (3H)bitolterol in man and dog. *Drug Metab Dispos* **4**:72-78.
- Turnbull LB, Teng L, Newman J, Bruce RB, and Maynard WR (1976) Disposition and metabolism of 3-(3-chlorophenoxy)-N-methylpyrrolidine [14C]-carboxamide in the rat, dog, and man. *Drug Metab Dispos* **4**:379-386.
- Zacchei AG, Weidner LL, Besselaar GH, and Raftery EB (1976) Physiological disposition and metabolic fate of a new antiarrhythmic agent, alpha, alpha-dimethyl-4-(alpha, alpha, beta, beta-tetrafluorophenethyl) benzylamine in the rat, dog, monkey, baboon, and man. *Drug Metab Dispos* **4**:387-401

1977

- DeLong AF, Smyth RD, Polk A, Nayak RK, Martin G, Douglas GH, and Reavey-Cantiwell NH (1977) Comparative metabolism of fenclorac in rat, dog, monkey, and man. *Drug Metab Dispos* **5**:122-131.
- Franklin RB, Dring LG, and Williams RT (1977) The metabolism of phenmetrazine in man and laboratory animals. *Drug Metab Dispos* **5**:223-233.
- Lin C, Li Y, McGlotten J, Morton JB, and Symchowicz S (1977) Isolation and identification of the major metabolite of albuterol in human urine. *Drug Metab Dispos* **5**:234-238.
- Tang BK, Inaba T, and Kalow W (1977) N-Hydroxylation of pentobarbital in man. *Drug Metab Dispos* **5**:71-74.

1978

- DeLong AF, Smyth RD, Polk A, Nayak RK, Martin G, Douglas GH, and Reavey-Cantiwell NH (1977) Comparative metabolism of fenclozac in rat, dog, monkey, and man. *Drug Metab Dispos* **5**:122-131.
- Franklin RB, Dring LG, and Williams RT (1977) The metabolism of phenmetrazine in man and laboratory animals. *Drug Metab Dispos* **5**:223-233.
- Lin C, Li Y, McGlotten J, Morton JB, and Symchowicz S (1977) Isolation and identification of the major metabolite of albuterol in human urine. *Drug Metab Dispos* **5**:234-238.
- Tang BK, Inaba T, and Kalow W (1977) N-Hydroxylation of pentobarbital in man. *Drug Metab Dispos* **5**:71-74.

1979

- Dugger HA and Heider JG (1979) Biotransformation of mazindol. II. Absorption and excretion in the dog and man. *Drug Metab Dispos* **7**:129-131.
- Dugger HA, Madrid VO, Talbot KC, Coombs RA, and Orwig BA (1979) Biotransformation of mazindol. III. Comparison of metabolism in rat, dog, and man. *Drug Metab Dispos* **7**:132-137.
- Eichelbaum M, Ende M, Remberg G, Schomerus M, and Dengler HJ (1979) The metabolism of DL-[14C]verapamil in man. *Drug Metab Dispos* **7**:145-148.
- Grindel JM, Migdalof BH, and Cressman WA (1979) The comparative metabolism and disposition of penfluridol-3H in the rat, rabbit, dog, and man. *Drug Metab Dispos* **7**:325-329.
- Martinelli E, Ferrari P, Ripamonti A, Tuan G, Perazzi A, and Assandri A (1979) Metabolism of deflazacort in the rat, dog and man. *Drug Metab Dispos* **7**:335-339.
- Tang BK, Kalow W, and Grey AA (1979) Metabolic fate of phenobarbital in man. N-Glucoside formation. *Drug Metab Dispos* **7**:315-318.
- Taylor DC, Cresswell PR, and Pepper ES (1979) The excretion and metabolism of metiamide in the rat, dog, and man. *Drug Metab Dispos* **7**:393-398.

1980

- Gaver RC and Deeb G (1980) Disposition of 14C-cefatrizine in man. *Drug Metab Dispos* **8**:157-162.
- Gaver RC, Vasiljev M, Wong H, Monkovic I, Swigor JE, Van Harken DR, and Smyth RD (1980) Disposition of parenteral butorphanol in man. *Drug Metab Dispos* **8**:230-235.
- Grindel JM, O'Neill PJ, Yorgey KA, Schwartz MH, McKown LA, Migdalof BH, and Wu WN (1980) The metabolism of zomepirac sodium. I. Disposition in laboratory animals and man. *Drug Metab Dispos* **8**:343-348.
- Mroszczak EJ and Lee FW (1980) Tiopinac absorption, distribution, excretion, and pharmacokinetics in man and animals. *Drug Metab Dispos* **8**:415-421.
- Selvig K and Bjerve KS (1980) Metabolism of proxyphylline in man. Isolation and identification of metabolites in urine. *Drug Metab Dispos* **8**:456-462.
- Tocco DJ, Duncan AE, deLuna FA, Smith JL, Walker RW, and Vandenneuvel WJ (1980) Timolol metabolism in man and laboratory animals. *Drug Metab Dispos* **8**:236-240.
- Vickers S, Duncan CA, Arison BH, Davies RO, Ferguson R, and Zacchei AG (1980) The metabolic disposition of (S)-2-(3-tert-butylamino-2-hydroxypropoxy)-3-cyanopyridine in rats, dogs, and humans. *Drug Metab Dispos* **8**:163-167.

Wu WN, Weaner LE, Kalbron J, O'Neill PJ, and Grindel JM (1980) The metabolism of zomepirac sodium. II. Isolation and identification of the urinary metabolites in rat, mouse, rhesus monkey, and man. *Drug Metab Dispos* **8**:349-352.

1981

de Jongh GD, van den Wildenberg HM, Nieuwenhuysse H, and van der Veen F (1981) The metabolism of mianserin in women, rabbits, and rats: identification of the major urinary metabolites. *Drug Metab Dispos* **9**:48-53.

Tökés L, Cho D, Maddox ML, Chaplin MD, and Chu NI (1981) Isolation and identification of an oxidatively defluorinated metabolite of flunisolide in man. *Drug Metab Dispos* **9**:485-486.

Wall ME, Brine DR, and Perez-Reyes M (1981) Metabolism and disposition of naltrexone in man after oral and intravenous administration. *Drug Metab Dispos* **9**:369-375.

Warrander A, Metcalf R, and Fromson JM (1981) The disposition and metabolism of 5-(4,5-dihydro-2-phenylbenz[e]indol-3-yl)salicylic acid (fendosal) in the rat, mouse, rabbit, dog, rhesus monkey, and man. *Drug Metab Dispos* **9**:161-167.

1982

Callahan MM, Robertson RS, Arnaud MJ, Branfman AR, McComish MF, and Yesair DW (1982) Human metabolism of [1-methyl-14C]- and [2-14C]caffeine after oral administration. *Drug Metab Dispos* **10**:417-423.

Egger H, Bartlett F, Yuan HP, and Karliner J (1982) Metabolism of pirofen in man, monkey, rat, and mouse. *Drug Metab Dispos* **10**:529-536.

Hoffmann KJ, Arfwidsson A, and Borg KO (1982) The metabolic disposition of the selective beta 1-adrenoceptor agonist prenalterol in mice, rats, dogs, and humans. *Drug Metab Dispos* **10**:173-179.

Klunk LJ, Riska PS, and Maynard DE (1982) The disposition and metabolism of 14C-tiamide . HCl in man. *Drug Metab Dispos* **10**:241-245.

Redalieu E, Bartlett MF, Waldes LM, Darrow WR, Egger H, and Wagner WE (1982) A study of methylphenidate in man with respect to its major metabolite. *Drug Metab Dispos* **10**:708-709.

Waller AR, Chasseaud LF, Bonn R, Taylor T, Darragh A, Girkin R, Down WH, and Doyle E (1982) Metabolic fate of the beta-blocker 14C-bupranolol in humans, dogs, and rhesus monkeys. *Drug Metab Dispos* **10**:51-54.

Waring RH and Mitchell SC (1982) The metabolism and elimination of S-carboxymethyl-L-cysteine in man. *Drug Metab Dispos* **10**:61-62.

1983

Branfman AR, McComish MF, Bruni RJ, Callahan MM, Robertson R, and Yesair DW (1983) Characterization of diaminouracil metabolites of caffeine in human urine. *Drug Metab Dispos* **11**:206-210.

Callahan MM, Robertson RS, Branfman AR, McComish MF, and Yesair DW (1983) Comparison of caffeine metabolism in three nonsmoking populations after oral administration of radiolabeled caffeine. *Drug Metab Dispos* **11**:211-217.

- Edsbäcker S, Jönsson S, Lindberg C, Ryrfeldt A, and Thalén A (1983) Metabolic pathways of the topical glucocorticoid budesonide in man. *Drug Metab Dispos* **11**:590-596.
- Emudianughe TS, Caldwell J, Sinclair KA, and Smith RL (1983) Species differences in the metabolic conjugation of clofibric acid and clofibrate in laboratory animals and man. *Drug Metab Dispos* **11**:97-102.
- Steffenrud S (1983) Metabolism of 9-deoxo-16,16-dimethyl-9-methylene prostaglandin E2 in humans. *Drug Metab Dispos* **11**:255-265.
- Wong FA, Bateman CP, Shaw CJ, and Patrick JE (1983) Biotransformation of bromperidol in rat, dog, and man. *Drug Metab Dispos* **11**:301-307.

1984

- Borondy PE and Michniewicz BM (1984) Metabolic disposition of isoxicam in man, monkey, dog, and rat. *Drug Metab Dispos* **12**:444-451.
- Lin C, Puar MS, Schuessler D, Pranatik BN, and Symchowicz S (1984) Isolation and identification of a metabolite of rosaramicin in human urine. *Drug Metab Dispos* **12**:51-56.
- Marten TR, Bourne GR, Miles GS, Shuker B, Rankine HD, and Dutka VN (1984) The metabolism of ICI 118,587, a partial agonist of beta 1-adrenoceptors, in mice, rats, rabbits, dogs, and humans. *Drug Metab Dispos* **12**:652-660.
- Maurer G, Loosli HR, Schreier E, and Keller B (1984) Disposition of cyclosporine in several animal species and man. I. Structural elucidation of its metabolites. *Drug Metab Dispos* **12**:120-126.
- McQuinn RL, Quarfoth GJ, Johnson JD, Banitt EH, Pathre SV, Chang SF, Ober RE, and Conard GJ (1984) Biotransformation and elimination of ¹⁴C-flecainide acetate in humans. *Drug Metab Dispos* **12**:414-420.
- Vickers S, Duncan CA, Ramjit HG, Dobrinska MR, Dollery CT, Gomez HJ, Leidy HL, and Vincek WC (1984) Metabolism of methyl dopa in man after oral administration of the pivaloyloxyethyl ester. *Drug Metab Dispos* **12**:242-246.
- Wall ME, Perez-Reyes M, Brine DR, and Cook CE (1984) Naltrexone disposition in man after subcutaneous administration. *Drug Metab Dispos* **12**:677-682.

1985

- Colburn WA, Vane FM, Bugge CJ, Carter DE, Bressler R, and Ehmann CW (1985) Pharmacokinetics of ¹⁴C-isotretinoin in healthy volunteers and volunteers with biliary T-tube drainage. *Drug Metab Dispos* **13**:327-332.
- Walle T, Walle UK, and Olanoff LS (1985) Quantitative account of propranolol metabolism in urine of normal man. *Drug Metab Dispos* **13**:204-209.
- Zampaglione N, Hilbert JM, Ning J, Chung M, Gural R, and Symchowicz S (1985) Disposition and metabolic fate of ¹⁴C-quazepam in man. *Drug Metab Dispos* **13**:25-29.

1986

- Knadler MP, Bergstrom RF, Callaghan JT, and Rubin A (1986) Nizatidine, an H₂-blocker. Its metabolism and disposition in man. *Drug Metab Dispos* **14**:175-182.

Massarella JW, Loh AC, Williams TH, Szuna AJ, Sandor D, Bressler R, and Leinweber FJ (1986) The disposition and metabolic fate of ¹⁴C-cibenzoline in man. *Drug Metab Dispos* **14**:59-64.

1987

Chanoine F, Grenot C, Sellier N, Barrett WE, Thompson RM, Fentiman AF, Nixon JR, Goyer R, and Junien JL (1987) Isolation and identification of major metabolites of tixocortol pivalate in human urine. *Drug Metab Dispos* **15**:868-876.

Corpet DE and Bories GF (1987) [³H]chloramphenicol metabolism in human volunteer: oxamic acid as a new major metabolite. *Drug Metab Dispos* **15**:925-927.

Ferdinandi ES, Cochran D, and Gedamke R (1987) Identification of the etodolac metabolite, 4-ureidoetodolac, in mouse, rat, dog, and man. *Drug Metab Dispos* **15**:921-924.

Mroszczak EJ, Lee FW, Combs D, Sarnquist FH, Huang BL, Wu AT, Tokes LG, Maddox ML, and Cho DK (1987) Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. *Drug Metab Dispos* **15**:618-626.

1988

Meuldermans W, Van Peer A, Hendrickx J, Lauwers W, Swysen E, Bockx M, Woestenborghs R, and Heykants J (1988) Excretion and biotransformation of cisapride in dogs and humans after oral administration. *Drug Metab Dispos* **16**:403-409.

Rubio FR, Fukuda EK, and Garland WA (1988) Urinary metabolites of rimantadine in humans. *Drug Metab Dispos* **16**:773-777.

Sweeny DJ, Martin M, and Diasio RB (1988) N-chenodeoxycholy-2-fluoro-beta-alanine: a biliary metabolite of 5-fluorouracil in humans. *Drug Metab Dispos* **16**:892-894.

Wu WN, Hills JF, Chang SY, and Ng KT (1988) Metabolism of bepridil in laboratory animals and humans. *Drug Metab Dispos* **16**:69-77.

1989

Duggan DE, Chen IW, Bayne WF, Halpin RA, Duncan CA, Schwartz MS, Stubbs RJ, and Vickers S (1989) The physiological disposition of lovastatin. *Drug Metab Dispos* **17**:166-173.

Egger H, Kochak G, Robertson P, Iannucci R, Rufino FA, and Stancato F (1989) Physiological disposition of CGS 16617 in rat, dog, and man. *Drug Metab Dispos* **17**:669-672.

Jajoo HK, Mayol RF, LaBudde JA, and Blair IA (1989) Metabolism of the antianxiety drug buspirone in human subjects. *Drug Metab Dispos* **17**:634-640.

Jeffcoat AR, Perez-Reyes M, Hill JM, Sadler BM, and Cook CE (1989) Cocaine disposition in humans after intravenous injection, nasal insufflation (snorting), or smoking. *Drug Metab Dispos* **17**:153-159.

Renberg L, Simonsson R, and Hoffmann KJ (1989) Identification of two main urinary metabolites of [¹⁴C]omeprazole in humans. *Drug Metab Dispos* **17**:69-76.

Vane FM, Buggé CJ, and Rodriguez LC (1989) Identification of etretinate metabolites in human bile. *Drug Metab Dispos* **17**:275-279.

1990

- Brown SY, Garland WA, and Fukuda EK (1990) Isolation and characterization of an unusual glucuronide conjugate of rimantadine. *Drug Metab Dispos* **18**:546-547.
- Ferrero JL, Bopp BA, Marsh KC, Quigley SC, Johnson MJ, Anderson DJ, Lamm JE, Tolman KG, Sanders SW, Cavanaugh JH, and et al. (1990) Metabolism and disposition of clarithromycin in man. *Drug Metab Dispos* **18**:441-446.
- Franz PM, Anliker SL, Callaghan JT, DeSante KA, Dhahir PH, Nelson RL, and Rubin A (1990) Disposition in humans of racemic piconadol, an opioid analgesic. *Drug Metab Dispos* **18**:968-973.
- Grislain L, Gele P, Bertrand M, Luijten W, Bromet N, Salvadori C, and Kamoun A (1990) The metabolic pathways of tianeptine, a new antidepressant, in healthy volunteers. *Drug Metab Dispos* **18**:804-808.
- Jajoo HK, Mayol RF, LaBudde JA, and Blair IA (1990) Structural characterization of urinary metabolites of the antiarrhythmic drug encainide in human subjects. *Drug Metab Dispos* **18**:28-35.
- Macrae PV, Kirrs M, Pullen FS, and Tarbit MH (1990) Characterization of a quaternary, N-glucuronide metabolite of the imidazole antifungal, tioconazole. *Drug Metab Dispos* **18**:1100-1102.
- Scatina JA, Wells DS, Kimmel HB, Kemper CJ, and Sisenwine SF (1990) Excretion and metabolism of recainam, a new anti-arrhythmic drug, in laboratory animals and humans. *Drug Metab Dispos* **18**:746-752.
- Vickers S, Duncan CA, Chen IW, Rosegay A, and Duggan DE (1990a) Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. *Drug Metab Dispos* **18**:138-145.
- Vickers S, Duncan CA, Vyas KP, Kari PH, Arison B, Prakash SR, Ramjit HG, Pitzenberger SM, Stokker G, and Duggan DE (1990b) In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. *Drug Metab Dispos* **18**:476-483.
- Weil A, Caldwell J, and Strolin-Benedetti M (1990) The metabolism and disposition of 14C-fenofibrate in human volunteers. *Drug Metab Dispos* **18**:115-120.

1991

- Barbhaiya RH, Knupp CA, Fogue ST, Matzke GR, Halstenson CE, Opsahl JA, and Pittman KA (1991) Disposition of the cephalosporin cefepime in normal and renally impaired subjects. *Drug Metab Dispos* **19**:68-73.
- Brammer KW, Coakley AJ, Jezequel SG, and Tarbit MH (1991) The disposition and metabolism of [14C]fluconazole in humans. *Drug Metab Dispos* **19**:764-767.
- Ehlhardt WJ (1991) Metabolism and disposition of the anticancer agent sulofenur in mouse, rat, monkey, and human. *Drug Metab Dispos* **19**:370-375.
- Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, and Weinstein SH (1991) Biotransformation of pravastatin sodium in humans. *Drug Metab Dispos* **19**:740-748.
- Mayol RF, Jajoo HK, Klunk LJ, and Blair IA (1991) Metabolism of the antipsychotic drug tiopirone in humans. *Drug Metab Dispos* **19**:394-399.

1992

- Carlin JR, Höglund P, Eriksson LO, Christofalo P, Gregoire SL, Taylor AM, and Andersson KE (1992) Disposition and pharmacokinetics of [14C]finasteride after oral administration in humans. *Drug Metab Dispos* **20**:148-155.
- Fischer V, Baldeck JP, and Tse FL (1992) Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans. *Drug Metab Dispos* **20**:603-607.

1993

- Adusumalli VE, Choi YM, Romanyshyn LA, Sparadoski RE, Jr., Wichmann JK, Wong KK, Kucharczyk N, and Sofia RD (1993) Isolation and identification of 3-carbamoyloxy-2-phenylpropionic acid as a major human urinary metabolite of felbamate. *Drug Metab Dispos* **21**:710-716.
- Dain JG, Fu E, Gorski J, Nicoletti J, and Scallen TJ (1993) Biotransformation of fluvastatin sodium in humans. *Drug Metab Dispos* **21**:567-572.
- Dixon CM, Saynor DA, Andrew PD, Oxford J, Bradbury A, and Tarbit MH (1993) Disposition of sumatriptan in laboratory animals and humans. *Drug Metab Dispos* **21**:761-769.
- Durham SL, Hoke JF, and Chen TM (1993) Pharmacokinetics and metabolism of vigabatrin following a single oral dose of [14C]vigabatrin in healthy male volunteers. *Drug Metab Dispos* **21**:480-484.
- Edwall B, Arvidsson A, Lake-Bakaar D, Lanbeck-Vallén K, and Yisak W (1993) Disposition of oral [14C]cefcanel daloxate hydrochloride in healthy male subjects. *Drug Metab Dispos* **21**:171-177.
- Franz PM, Mattiuz EL, Hatcher BL, DeSante KA, Breau AP, Occolowitz JL, Dorman DE, Schmid CR, Goldberg MJ, and Rubin A (1993) Disposition of zatosetron, a serotonin (5-HT₃) receptor antagonist, in humans. *Drug Metab Dispos* **21**:249-254.
- Halpin RA, Ulm EH, Till AE, Kari PH, Vyas KP, Hunninghake DB, and Duggan DE (1993) Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human. *Drug Metab Dispos* **21**:1003-1011.
- Krause W, Kühne G, Jakobs U, and Hoyer GA (1993) Biotransformation of the antidepressant DL-rolopram. I. Isolation and identification of metabolites from rat, monkey, and human urine. *Drug Metab Dispos* **21**:682-689.
- Manchee GR, Barrow A, Kulkarni S, Palmer E, Oxford J, Colthup PV, Maconochie JG, and Tarbit MH (1993) Disposition of salmeterol xinafoate in laboratory animals and humans. *Drug Metab Dispos* **21**:1022-1028.
- Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, and Heykants J (1993) Absorption, metabolism, and excretion of risperidone in humans. *Drug Metab Dispos* **21**:1134-1141.
- Thomassin J, Battaglia R, Allievi C, Castelli MG, and Strolin Benedetti M (1993) In vivo glucuronidation in rat and humans of 5,6-dihydro-7-(1H-imidazol-1-yl)-naphthalene-2-carboxylic acid, a selective inhibitor of thromboxane synthase. *Drug Metab Dispos* **21**:151-155.
- Turcan RG, Hillbeck D, Hartley TE, Gilbert PJ, Coe RA, Troke JA, and Vose CW (1993) Disposition of [14C]velnacrine maleate in rats, dogs, and humans. *Drug Metab Dispos* **21**:1037-1047.

1994

- Cheng H, Schwartz MS, Vickers S, Gilbert JD, Amin RD, Depuy B, Liu L, Rogers JD, Pond SM, Duncan CA, and et al. (1994) Metabolic disposition of simvastatin in patients with T-tube drainage. *Drug Metab Dispos* **22**:139-142.
- Mangold JB, Schran HF, and Tse FL (1994) Pharmacokinetics and metabolism of cyclosporin G in humans. *Drug Metab Dispos* **22**:873-879.
- Mayol RF, Cole CA, Luke GM, Colson KL, and Kerns EH (1994) Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. *Drug Metab Dispos* **22**:304-311.

1995

- Reith MK, Sproles GD, and Cheng LK (1995) Human metabolism of dolasetron mesylate, a 5-HT₃ receptor antagonist. *Drug Metab Dispos* **23**:806-812.
- Schmid J, Busch U, Heinzl G, Bozler G, Kaschke S, and Kummer M (1995) Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. *Drug Metab Dispos* **23**:1206-1213.
- Walle T, Walle UK, Kumar GN, and Bhalla KN (1995) Taxol metabolism and disposition in cancer patients. *Drug Metab Dispos* **23**:506-512.

1996

- Balani SK, Woolf EJ, Hoagland VL, Sturgill MG, Deutsch PJ, Yeh KC, and Lin JH (1996) Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans. *Drug Metab Dispos* **24**:1389-1394.
- Barbhaiya RH, Dandekar KA, and Greene DS (1996) Pharmacokinetics, absolute bioavailability, and disposition of [¹⁴C]nefazodone in humans. *Drug Metab Dispos* **24**:91-95.
- Cooper AE, Gray AJ, Collington J, Seddon H, Beattie I, and Logan CJ (1996) Excretion and metabolism of tipredane, a novel glucocorticoid, in the rat, mouse, monkey, and human. *Drug Metab Dispos* **24**:1071-1080.
- Halldin MM, Bredberg E, Angelin B, Arvidsson T, Askemark Y, Elofsson S, and Widman M (1996) Metabolism and excretion of ropivacaine in humans. *Drug Metab Dispos* **24**:962-968.

1997

- Dain JG, Nicoletti J, and Ballard F (1997) Biotransformation of clozapine in humans. *Drug Metab Dispos* **25**:603-609.
- Dalvie DK, Khosla N, and Vincent J (1997) Excretion and metabolism of trovafloxacin in humans. *Drug Metab Dispos* **25**:423-427.
- Denissen JF, Grabowski BA, Johnson MK, Buko AM, Kempf DJ, Thomas SB, and Surber BW (1997) Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. *Drug Metab Dispos* **25**:489-501.
- Kassahun K, Mattiuz E, Nyhart E, Jr., Obermeyer B, Gillespie T, Murphy A, Goodwin RM, Tupper D, Callaghan JT, and Lemberger L (1997) Disposition and biotransformation of the antipsychotic agent olanzapine in humans. *Drug Metab Dispos* **25**:81-93.
- Marathe PH, Greene DS, and Barbhaiya RH (1997) Disposition of [¹⁴C]javitriptan in rats and humans. *Drug Metab Dispos* **25**:881-888.

Pool WF, Reily MD, Bjorge SM, and Woolf TF (1997) Metabolic disposition of the cognition activator tacrine in rats, dogs, and humans. Species comparisons. *Drug Metab Dispos* **25**:590-597.

Prakash C, Kamel A, and Cui D (1997a) Characterization of the novel benzisothiazole ring-cleaved products of the antipsychotic drug ziprasidone. *Drug Metab Dispos* **25**:897-901.

Prakash C, Kamel A, Gummerus J, and Wilner K (1997b) Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. *Drug Metab Dispos* **25**:863-872.

1998

Chando TJ, Everett DW, Kahle AD, Starrett AM, Vachharajani N, Shyu WC, Kripalani KJ, and Barbhaiya RH (1998) Biotransformation of irbesartan in man. *Drug Metab Dispos* **26**:408-417.

Prakash C, Cui D, Baxter JG, Bright GM, Miceli J, and Wilner K (1998) Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers. *Drug Metab Dispos* **26**:448-456.

Reith K, Keung A, Toren PC, Cheng L, Eller MG, and Weir SJ (1998) Disposition and metabolism of ¹⁴C-rifapentine in healthy volunteers. *Drug Metab Dispos* **26**:732-738.

1999

Christensen EB, Andersen JB, Pedersen H, Jensen KG, and Dalgaard L (1999) Metabolites of [(14)C]-5-(2-ethyl-2H-tetrazol-5-yl)-1-methyl-1,2,3, 6-tetrahydropyridine in mice, rats, dogs, and humans. *Drug Metab Dispos* **27**:1341-1349.

Gelderblom H, Verweij J, Brouwer E, Pillay M, de Bruijn P, Nooter K, Stoter G, and Sparreboom A (1999) Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function. *Drug Metab Dispos* **27**:1300-1305.

Möller A, Iwasaki K, Kawamura A, Teramura Y, Shiraga T, Hata T, Schäfer A, and Undre NA (1999) The disposition of ¹⁴C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. *Drug Metab Dispos* **27**:633-636.

Riska P, Lamson M, MacGregor T, Sabo J, Hattox S, Pav J, and Keirns J (1999) Disposition and biotransformation of the antiretroviral drug nevirapine in humans. *Drug Metab Dispos* **27**:895-901.

Rosenborg J, Larsson P, Tegnér K, and Hallström G (1999) Mass balance and metabolism of [(3)H]Formoterol in healthy men after combined i.v. and oral administration-mimicking inhalation. *Drug Metab Dispos* **27**:1104-1116.

Weber C, Gasser R, and Hopfgartner G (1999) Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. *Drug Metab Dispos* **27**:810-815.

2000

Balani SK, Xu X, Arison BH, Silva MV, Gries A, DeLuna FA, Cui D, Kari PH, Ly T, Hop CE, Singh R, Wallace MA, Dean DC, Lin JH, Pearson PG, and Baillie TA (2000) Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. *Drug Metab Dispos* **28**:1274-1278.

- Cox PJ, Ryan DA, Hollis FJ, Harris AM, Miller AK, Vousden M, and Cowley H (2000) Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. *Drug Metab Dispos* **28**:772-780.
- Dockens RC, Santone KS, Mitroka JG, Morrison RA, Jemal M, Greene DS, and Barbhuiya RH (2000) Disposition of radiolabeled ifetroban in rats, dogs, monkeys, and humans. *Drug Metab Dispos* **28**:973-980.
- Paulson SK, Hribar JD, Liu NW, Hajdu E, Bible RH, Jr., Piergies A, and Karim A (2000) Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers. *Drug Metab Dispos* **28**:308-314.
- Slatter JG, Schaaf LJ, Sams JP, Feenstra KL, Johnson MG, Bombardt PA, Cathcart KS, Verburg MT, Pearson LK, Compton LD, Miller LL, Baker DS, Pesheck CV, and Lord RS, 3rd (2000) Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. *Drug Metab Dispos* **28**:423-433.
- Vyas KP, Halpin RA, Geer LA, Ellis JD, Liu L, Cheng H, Chavez-Eng C, Matuszewski BK, Varga SL, Guiblin AR, and Rogers JD (2000) Disposition and pharmacokinetics of the antimigraine drug, rizatriptan, in humans. *Drug Metab Dispos* **28**:89-95.

2001

- Iyer RA, Mitroka J, Malhotra B, Bonacorsi S, Jr., Waller SC, Rinehart JK, Roongta VA, and Kripalani K (2001) Metabolism of [(14)C]omapatrilat, a sulfhydryl-containing vasopeptidase inhibitor in humans. *Drug Metab Dispos* **29**:60-69.
- Joshi AS, Pieniaszek HJ, Jr., Vokes EE, Vogelzang NJ, Davidson AF, Richards LE, Chai MF, Finizio M, and Ratain MJ (2001) Elimination pathways of [14C]losoxantrone in four cancer patients. *Drug Metab Dispos* **29**:96-99.
- Slatter JG, Stalker DJ, Feenstra KL, Welshman IR, Bruss JB, Sams JP, Johnson MG, Sanders PE, Hauer MJ, Fagerness PE, Stryd RP, Peng GW, and Shobe EM (2001) Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. *Drug Metab Dispos* **29**:1136-1145.
- Weaver ML, Orwig BA, Rodriguez LC, Graham ED, Chin JA, Shapiro MJ, McLeod JF, and Mangold JB (2001) Pharmacokinetics and metabolism of nateglinide in humans. *Drug Metab Dispos* **29**:415-421.

2002

- Garner RC, Goris I, Laenen AA, Vanhoutte E, Meuldermans W, Gregory S, Garner JV, Leong D, Whattam M, Calam A, and Snel CA (2002) Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. *Drug Metab Dispos* **30**:823-830.
- Halpin RA, Porras AG, Geer LA, Davis MR, Cui D, Doss GA, Woolf E, Musson D, Matthews C, Mazenko R, Schwartz JI, Lasseter KC, Vyas KP, and Baillie TA (2002) The

- disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects. *Drug Metab Dispos* **30**:684-693.
- Mannens GS, Snel CA, Hendrickx J, Verhaeghe T, Le Jeune L, Bode W, van Beijsterveldt L, Lavrijsen K, Leempoels J, Van Osselaer N, Van Peer A, and Meuldermans W (2002) The metabolism and excretion of galantamine in rats, dogs, and humans. *Drug Metab Dispos* **30**:553-563.
- Patrick JE, Kosoglou T, Stauber KL, Alton KB, Maxwell SE, Zhu Y, Statkevich P, Iannucci R, Chowdhury S, Affrime M, and Cayen MN (2002) Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. *Drug Metab Dispos* **30**:430-437.
- Vos RM, Krebbers SF, Verhoeven CH, and Delbressine LP (2002) The in vivo human metabolism of tibolone. *Drug Metab Dispos* **30**:106-112.
- Yuan JJ, Yang DC, Zhang JY, Bible R, Jr., Karim A, and Findlay JW (2002) Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human. *Drug Metab Dispos* **30**:1013-1021.

2003

- Cook CS, Berry LM, Bible RH, Hribar JD, Hajdu E, and Liu NW (2003) Pharmacokinetics and metabolism of [¹⁴C]eplerenone after oral administration to humans. *Drug Metab Dispos* **31**:1448-1455.
- Eriksson UG, Bredberg U, Hoffmann KJ, Thuresson A, Gabrielsson M, Ericsson H, Ahnoff M, Gislén K, Fager G, and Gustafsson D (2003) Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. *Drug Metab Dispos* **31**:294-305.
- He MM, Abraham TL, Lindsay TJ, Schaefer HC, Pouliquen IJ, Payne C, Czeskis B, Shipley LA, Oliver SD, and Mitchell MI (2003) Metabolism and disposition of the antihypertensive agent moxonidine in humans. *Drug Metab Dispos* **31**:334-342.
- Iyer RA, Malhotra B, Khan S, Mitroka J, Bonacorsi S, Jr., Waller SC, Rinehart JK, and Kripalani K (2003) Comparative biotransformation of radiolabeled [(14)C]omapatrilat and stable-labeled [(13)C(2)]omapatrilat after oral administration to rats, dogs, and humans. *Drug Metab Dispos* **31**:67-75.
- Lantz RJ, Gillespie TA, Rash TJ, Kuo F, Skinner M, Kuan HY, and Knadler MP (2003) Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. *Drug Metab Dispos* **31**:1142-1150.
- Rodrigues AD, Halpin RA, Geer LA, Cui D, Woolf EJ, Matthews CZ, Gottesdiener KM, Larson PJ, Lasseter KC, and Agrawal NG (2003) Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. *Drug Metab Dispos* **31**:224-232.
- Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman AN, Smith DA, Walker DK, and Wood N (2003) The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. *Drug Metab Dispos* **31**:731-741.
- Sauer JM, Ponsler GD, Mattiuz EL, Long AJ, Witcher JW, Thomasson HR, and Desante KA (2003) Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. *Drug Metab Dispos* **31**:98-107.

2004

- Bu HZ, Pool WF, Wu EY, Raber SR, Amantea MA, and Shetty BV (2004) Metabolism and excretion of capravirine, a new non-nucleoside reverse transcriptase inhibitor, alone and in combination with ritonavir in healthy volunteers. *Drug Metab Dispos* **32**:689-698.
- Ericsson H, Hamrén B, Bergstrand S, Elebring M, Fryklund L, Heijer M, and Ohman KP (2004) Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans. *Drug Metab Dispos* **32**:923-929.
- Harrison A, Betts A, Fenner K, Beaumont K, Edgington A, Roffey S, Davis J, Comby P, and Morgan P (2004) Nonlinear oral pharmacokinetics of the alpha-antagonist 4-amino-5-(4-fluorophenyl)-6,7-dimethoxy-2-[4-(morpholinocarbonyl)-perhydro-1,4-diazepin-1-yl]quinoline in humans: use of preclinical data to rationalize clinical observations. *Drug Metab Dispos* **32**:197-204.
- Kumar GN, Sproul C, Poppe L, Turner S, Gohdes M, Ghoborah H, Padhi D, and Roskos L (2004) Metabolism and disposition of calcimimetic agent cinacalcet HCl in humans and animal models. *Drug Metab Dispos* **32**:1491-1500.
- Mangold JB, Gu H, Rodriguez LC, Bonner J, Dickson J, and Rordorf C (2004) Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. *Drug Metab Dispos* **32**:566-571.
- Walle T, Hsieh F, DeLegge MH, Oatis JE, Jr., and Walle UK (2004) High absorption but very low bioavailability of oral resveratrol in humans. *Drug Metab Dispos* **32**:1377-1382.

2005

- Gschwind HP, Pfaar U, Waldmeier F, Zollinger M, Sayer C, Zbinden P, Hayes M, Pokorny R, Seiberling M, Ben-Am M, Peng B, and Gross G (2005) Metabolism and disposition of imatinib mesylate in healthy volunteers. *Drug Metab Dispos* **33**:1503-1512.
- Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, and Smith DA (2005) Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. *Drug Metab Dispos* **33**:587-595.
- Zhang D, Krishna R, Wang L, Zeng J, Mitroka J, Dai R, Narasimhan N, Reeves RA, Srinivas NR, and Klunk LJ (2005) Metabolism, pharmacokinetics, and protein covalent binding of radiolabeled MaxiPost (BMS-204352) in humans. *Drug Metab Dispos* **33**:83-93.

2006

- Burkey JL, Campanale KM, Barbuch R, O'Bannon D, Rash J, Benson C, and Small D (2006) Disposition of [¹⁴C]ruboxistaurin in humans. *Drug Metab Dispos* **34**:1909-1917.
- Kochansky CJ, Rippley RK, Yan KX, Song H, Wallace MA, Dean D, Jones AN, Lasseter K, Schwartz J, Vincent SH, Franklin RB, and Wagner J (2006) Absorption, metabolism, and excretion of [¹⁴C]MK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in humans. *Drug Metab Dispos* **34**:1457-1461.
- Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN, Zandi KS, Miller S, and Coe JW (2006) Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. *Drug Metab Dispos* **34**:121-130.

- Paci A, Rezai K, Deroussent A, De Valeriola D, Re M, Weill S, Cvitkovic E, Kahatt C, Shah A, Waters S, Weems G, Vassal G, and Lokiec F (2006) Pharmacokinetics, metabolism, and routes of excretion of intravenous iriffulven in patients with advanced solid tumors. *Drug Metab Dispos* **34**:1918-1926.
- Polsky-Fisher SL, Vickers S, Cui D, Subramanian R, Arison BH, Agrawal NG, Goel TV, Vessey LK, Murphy MG, Lasseter KC, Simpson RC, Vega JM, and Rodrigues AD (2006) Metabolism and disposition of a potent and selective GABA-A α 2/3 receptor agonist in healthy male volunteers. *Drug Metab Dispos* **34**:1004-1011.
- Wait JC, Vaccharajani N, Mitroka J, Jemal M, Khan S, Bonacorsi SJ, Rinehart JK, and Iyer RA (2006) Metabolism of [14 C]gemopatrilat after oral administration to rats, dogs, and humans. *Drug Metab Dispos* **34**:961-970.
- Wang L, Zhang D, Swaminathan A, Xue Y, Cheng PT, Wu S, Mosqueda-Garcia R, Aurang C, Everett DW, and Humphreys WG (2006) Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection. *Drug Metab Dispos* **34**:427-439.

2007

- Colizza K, Awad M, and Kamel A (2007) Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy. *Drug Metab Dispos* **35**:884-897.
- Farid NA, Smith RL, Gillespie TA, Rash TJ, Blair PE, Kurihara A, and Goldberg MJ (2007) The disposition of prasugrel, a novel thienopyridine, in humans. *Drug Metab Dispos* **35**:1096-1104.
- Hoffmann M, DeMaio W, Jordan RA, Talaat R, Harper D, Speth J, and Scatina J (2007) Metabolism, excretion, and pharmacokinetics of [14 C]tigecycline, a first-in-class glycylicline antibiotic, after intravenous infusion to healthy male subjects. *Drug Metab Dispos* **35**:1543-1553.
- Karanam B, Madeira M, Bradley S, Wenning L, Desai R, Soli E, Schenk D, Jones A, Dean B, Doss G, Garrett G, Crumley T, Nirula A, and Lai E (2007) Absorption, metabolism, and excretion of [(14C)MK-0524, a prostaglandin D(2) receptor antagonist, in humans. *Drug Metab Dispos* **35**:1196-1202.
- Kassahun K, McIntosh I, Cui D, Hreniuk D, Merschman S, Lasseter K, Azrolan N, Iwamoto M, Wagner JA, and Wenning LA (2007) Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. *Drug Metab Dispos* **35**:1657-1663.
- Mannens GS, Hendrickx J, Janssen CG, Chien S, Van Hoof B, Verhaeghe T, Kao M, Kelley MF, Goris I, Bockx M, Verreet B, Bialer M, and Meuldermans W (2007) The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans. *Drug Metab Dispos* **35**:554-565.
- Ohmori S, Miura M, Toriumi C, Satoh Y, and Ooie T (2007) Absorption, metabolism, and excretion of [14 C]imidafenacin, a new compound for treatment of overactive bladder, after oral administration to healthy male subjects. *Drug Metab Dispos* **35**:1624-1633.
- Prakash C, O'Donnell J, and Khojasteh-Bakht SC (2007) Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy

- male volunteers: characterization of polar metabolites by chemical derivatization with dansyl chloride. *Drug Metab Dispos* **35**:1071-1080.
- Shaffer CL, Gunduz M, Scialis RJ, and Fang AF (2007) Metabolism and disposition of a selective alpha(7) nicotinic acetylcholine receptor agonist in humans. *Drug Metab Dispos* **35**:1188-1195.
- Vincent SH, Reed JR, Bergman AJ, Elmore CS, Zhu B, Xu S, Ebel D, Larson P, Zeng W, Chen L, Dilzer S, Lasseter K, Gottesdiener K, Wagner JA, and Herman GA (2007) Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. *Drug Metab Dispos* **35**:533-538.
- Waldmeier F, Glaenzel U, Wirz B, Oberer L, Schmid D, Seiberling M, Valencia J, Riviere GJ, End P, and Vaidyanathan S (2007) Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. *Drug Metab Dispos* **35**:1418-1428.
- Zhang D, Wang L, Raghavan N, Zhang H, Li W, Cheng PT, Yao M, Zhang L, Zhu M, Bonacorsi S, Yeola S, Mitroka J, Hariharan N, Hosagrahara V, Chandrasena G, Shyu WC, and Humphreys WG (2007) Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling. *Drug Metab Dispos* **35**:150-167.

2008

- Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, and Roth W (2008) The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. *Drug Metab Dispos* **36**:386-399.
- Christopher LJ, Cui D, Wu C, Luo R, Manning JA, Bonacorsi SJ, Lago M, Allentoff A, Lee FY, McCann B, Galbraith S, Reitberg DP, He K, Barros A, Jr., Blackwood-Chirchir A, Humphreys WG, and Iyer RA (2008) Metabolism and disposition of dasatinib after oral administration to humans. *Drug Metab Dispos* **36**:1357-1364.
- Dalvie D, Chen W, Zhang C, Vaz AD, Smolarek TA, Cox LM, Lin J, and Obach RS (2008) Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans. *Drug Metab Dispos* **36**:2185-2198.
- Hughes SC, Shardlow PC, Hollis FJ, Scott RJ, Motivaras DS, Allen A, and Rousell VM (2008) Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. *Drug Metab Dispos* **36**:2337-2344.
- Krieter PA, Gohdes M, Musick TJ, Duncanson FP, and Bridson WE (2008) Pharmacokinetics, disposition, and metabolism of bicifadine in humans. *Drug Metab Dispos* **36**:252-259.
- Prakash C, Johnson KA, and Gardner MJ (2008) Disposition of lasofoxifene, a next-generation selective estrogen receptor modulator, in healthy male subjects. *Drug Metab Dispos* **36**:1218-1226.
- Sargentini-Maier ML, Espié P, Coquette A, and Stockis A (2008) Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. *Drug Metab Dispos* **36**:36-45.
- Shaffer CL, Gunduz M, Vaz AD, Venkatakrishnan K, and Burstein AH (2008) Metabolism and disposition of a gamma-aminobutyric acid type A receptor partial agonist in humans. *Drug Metab Dispos* **36**:655-662.

Vermeir M, Naessens I, Remmerie B, Mannens G, Hendrickx J, Sterkens P, Talluri K, Boom S, Eerdeken M, van Osselaer N, and Cleton A (2008) Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. *Drug Metab Dispos* **36**:769-779.

Zhu M, Whigan DB, Chang SY, and Dockens RC (2008) Disposition and metabolism of [¹⁴C]brasofensine in rats, monkeys, and humans. *Drug Metab Dispos* **36**:24-35.

2009

Cawello W, Braun M, and Boekens H (2009) Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. *Drug Metab Dispos* **37**:2055-2060.

Chandrasekaran A, McKeand WE, Sullivan P, DeMaio W, Stoltz R, and Scatina J (2009) Metabolic disposition of [¹⁴C]bazedoxifene in healthy postmenopausal women. *Drug Metab Dispos* **37**:1219-1225.

He H, Tran P, Yin H, Smith H, Batard Y, Wang L, Einolf H, Gu H, Mangold JB, Fischer V, and Howard D (2009) Absorption, metabolism, and excretion of [¹⁴C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. *Drug Metab Dispos* **37**:536-544.

Pellegatti M, Bordini E, Fizzotti P, Roberts A, and Johnson BM (2009) Disposition and metabolism of radiolabeled casopitant in humans. *Drug Metab Dispos* **37**:1635-1645.

Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, and Zhang D (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. *Drug Metab Dispos* **37**:74-81.

Umehara K, Shirai N, Iwatsubo T, Noguchi K, Usui T, and Kamimura H (2009) Identification of human metabolites of (-)-N-{2-[(R)-3-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a novel If channel inhibitor, and investigation of the transporter-mediated renal and hepatic excretion of these metabolites. *Drug Metab Dispos* **37**:1646-1657.

Vermeir M, Lachau-Durand S, Mannens G, Cuyckens F, van Hoof B, and Raouf A (2009) Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects. *Drug Metab Dispos* **37**:809-820.

Weinz C, Schwarz T, Kubitzka D, Mueck W, and Lang D (2009) Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans. *Drug Metab Dispos* **37**:1056-1064.

Zhang D, He K, Raghavan N, Wang L, Mitroka J, Maxwell BD, Knabb RM, Frost C, Schuster A, Hao F, Gu Z, Humphreys WG, and Grossman SJ (2009) Comparative metabolism of ¹⁴C-labeled apixaban in mice, rats, rabbits, dogs, and humans. *Drug Metab Dispos* **37**:1738-1748.

2010

Blech S, Ludwig-Schwellinger E, Gräfe-Mody EU, Withopf B, and Wagner K (2010) The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. *Drug Metab Dispos* **38**:667-678.

- Chandrasekaran A, Tong Z, Li H, Erve JC, DeMaio W, Goljer I, McConnell O, Rotshteyn Y, Hultin T, Talaat R, and Scatina J (2010) Metabolism of intravenous methylnaltrexone in mice, rats, dogs, and humans. *Drug Metab Dispos* **38**:606-616.
- Christopher LJ, Hong H, Vakkalagadda BJ, Clemens PL, Su H, Roongta V, Allentoff A, Sun H, Heller K, Harbison CT, Iyer RA, Humphreys WG, Wong T, and Zhang S (2010) Metabolism and disposition of [¹⁴C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans. *Drug Metab Dispos* **38**:2049-2059.
- Dalvie D, Zhang C, Chen W, Smolarek T, Obach RS, and Loi CM (2010) Cross-species comparison of the metabolism and excretion of zoniporide: contribution of aldehyde oxidase to interspecies differences. *Drug Metab Dispos* **38**:641-654.
- Kumar S, Tan EY, Hartmann G, Biddle Z, Bergman AJ, Dru J, Ho JZ, Jones AN, Staskiewicz SJ, Braun MP, Karanam B, Dean DC, Gendrano IN, Graves MW, Wagner JA, and Krishna R (2010) Metabolism and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. *Drug Metab Dispos* **38**:474-483.
- Malm-Erjefält M, Björnsdóttir I, Vanggaard J, Helleberg H, Larsen U, Oosterhuis B, van Lier JJ, Zdravkovic M, and Olsen AK (2010) Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. *Drug Metab Dispos* **38**:1944-1953.
- Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W, Komoroski B, Kasichayanula S, Discenza L, Washburn W, Meng W, Ellsworth BA, Whaley JM, and Humphreys WG (2010) In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. *Drug Metab Dispos* **38**:405-414.
- Shilling AD, Nedza FM, Emm T, Diamond S, McKeever E, Punwani N, Williams W, Arvanitis A, Galya LG, Li M, Shepard S, Rodgers J, Yue TY, and Yeleswaram S (2010) Metabolism, excretion, and pharmacokinetics of [¹⁴C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. *Drug Metab Dispos* **38**:2023-2031.
- Sweeny DJ, Li W, Clough J, Bhamidipati S, Singh R, Park G, Baluom M, Grossbard E, and Lau DT (2010) Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation. *Drug Metab Dispos* **38**:1166-1176.
- Teng R, Oliver S, Hayes MA, and Butler K (2010) Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. *Drug Metab Dispos* **38**:1514-1521.
- Vourvahis M, Gleave M, Nedderman AN, Hyland R, Gardner I, Howard M, Kempshall S, Collins C, and LaBadie R (2010) Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C₂)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [¹⁴C]Lersivirine to healthy volunteers. *Drug Metab Dispos* **38**:789-800.

2011

- Bowersox SS, Lightning LK, Rao S, Palme M, Ellis D, Coleman R, Davies AM, Kumaraswamy P, and Druzgala P (2011) Metabolism and pharmacokinetics of naronapride (ATI-7505), a serotonin 5-HT(4) receptor agonist for gastrointestinal motility disorders. *Drug Metab Dispos* **39**:1170-1180.

- Deng Y, Madatian A, Wire MB, Bowen C, Park JW, Williams D, Peng B, Schubert E, Gorycki F, Levy M, and Gorycki PD (2011) Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects. *Drug Metab Dispos* **39**:1734-1746.
- Gong J, Gan J, Caceres-Cortes J, Christopher LJ, Arora V, Masson E, Williams D, Pursley J, Allentoff A, Lago M, Tran SB, and Iyer RA (2011) Metabolism and disposition of [¹⁴C]brivanib alaninate after oral administration to rats, monkeys, and humans. *Drug Metab Dispos* **39**:891-903.
- Graham RA, Lum BL, Morrison G, Chang I, Jorga K, Dean B, Shin YG, Yue Q, Mulder T, Malhi V, Xie M, Low JA, and Hop CE (2011) A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. *Drug Metab Dispos* **39**:1460-1467.
- Renzulli C, Nash M, Wright M, Thomas S, Zamuner S, Pellegatti M, Bettica P, and Boyle G (2011) Disposition and metabolism of [¹⁴C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans. *Drug Metab Dispos* **39**:215-227.
- van de Wetering-Krebbers SF, Jacobs PL, Kemperman GJ, Spaans E, Peeters PA, Delbressine LP, and van Iersel ML (2011) Metabolism and excretion of asenapine in healthy male subjects. *Drug Metab Dispos* **39**:580-590.
- Wang L, Munsick C, Chen S, Bonacorsi S, Cheng PT, Humphreys WG, and Zhang D (2011) Metabolism and disposition of ¹⁴C-labeled peliglitazar in humans. *Drug Metab Dispos* **39**:228-238.
- Zhang D, Raghavan N, Wang L, Xue Y, Obermeier M, Chen S, Tao S, Zhang H, Cheng PT, Li W, Ramanathan R, Yang Z, and Humphreys WG (2011) Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: how circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment. *Drug Metab Dispos* **39**:123-131.
- Zollinger M, Gschwind HP, Jin Y, Sayer C, Zécri F, and Hartmann S (2011) Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways. *Drug Metab Dispos* **39**:199-207.

2012

- Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, and Mendell J (2012) Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. *Drug Metab Dispos* **40**:2250-2255.
- Castellino S, O'Mara M, Koch K, Borts DJ, Bowers GD, and MacLauchlin C (2012) Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity. *Drug Metab Dispos* **40**:139-150.
- Dubbelman AC, Jansen RS, Rosing H, Darwish M, Hellriegel E, Robertson P, Jr., Schellens JH, and Beijnen JH (2012a) Metabolite profiling of bendamustine in urine of cancer patients after administration of [¹⁴C]bendamustine. *Drug Metab Dispos* **40**:1297-1307.
- Dubbelman AC, Rosing H, Jansen RS, Mergui-Roelvink M, Huitema AD, Koetz B, Lymboura M, Reyderman L, Lopez-Anaya A, Schellens JH, and Beijnen JH (2012b) Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors. *Drug Metab Dispos* **40**:313-321.

- Duchateau G, Cochrane B, Windebank S, Herudzinska J, Sanghera D, Burian A, Müller M, Zeitlinger M, and Lappin G (2012) Absolute oral bioavailability and metabolic turnover of β -sitosterol in healthy subjects. *Drug Metab Dispos* **40**:2026-2030.
- Kagan M, Dain J, Peng L, and Reynolds C (2012) Metabolism and pharmacokinetics of indacaterol in humans. *Drug Metab Dispos* **40**:1712-1722.
- Li F, Chin C, Wangsa J, and Ho J (2012) Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride. *Drug Metab Dispos* **40**:1723-1735.
- Miao Z, Sun H, Liras J, and Prakash C (2012) Excretion, metabolism, and pharmacokinetics of 1-(8-(2-chlorophenyl)-9-(4-chlorophenyl)-9H-purin-6-yl)-4-(ethylamino)piperidine-4-carboxamide, a selective cannabinoid receptor antagonist, in healthy male volunteers. *Drug Metab Dispos* **40**:568-578.
- Prakash C, Li Z, Orlandi C, and Klunk L (2012) Assessment of exposure of metabolites in preclinical species and humans at steady state from the single-dose radiolabeled absorption, distribution, metabolism, and excretion studies: a case study. *Drug Metab Dispos* **40**:1308-1320.
- Sharma R, Sun H, Piotrowski DW, Ryder TF, Doran SD, Dai H, and Prakash C (2012) Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human. *Drug Metab Dispos* **40**:2143-2161.
- Sigafoos JF, Bowers GD, Castellino S, Culp AG, Wagner DS, Reese MJ, Humphreys JE, Hussey EK, O'Connor Semmes RL, Kapur A, Tao W, Dobbins RL, and Polli JW (2012) Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies. *Drug Metab Dispos* **40**:2090-2101.
- Speed B, Bu HZ, Pool WF, Peng GW, Wu EY, Patyna S, Bello C, and Kang P (2012) Pharmacokinetics, distribution, and metabolism of [¹⁴C]sunitinib in rats, monkeys, and humans. *Drug Metab Dispos* **40**:539-555.
- Su H, Boulton DW, Barros A, Jr., Wang L, Cao K, Bonacorsi SJ, Jr., Iyer RA, Humphreys WG, and Christopher LJ (2012) Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human. *Drug Metab Dispos* **40**:1345-1356.
- Takusagawa S, van Lier JJ, Suzuki K, Nagata M, Meijer J, Krauwinkel W, Schaddelee M, Sekiguchi M, Miyashita A, Iwatsubo T, van Gelderen M, and Usui T (2012) Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective $\beta(3)$ -adrenoceptor agonist, after oral administration to healthy male volunteers. *Drug Metab Dispos* **40**:815-824.
- Yi P, Rehmel JF, Cassidy K, Hadden C, Campanale K, Patel N, and Johnson J (2012) Disposition and metabolism of LY2452473, a selective androgen receptor modulator, in humans. *Drug Metab Dispos* **40**:2354-2364.

2013

- Bershas DA, Ouellet D, Mamaril-Fishman DB, Nebot N, Carson SW, Blackman SC, Morrison RA, Adams JL, Jurusik KE, Knecht DM, Gorycki PD, and Richards-Peterson LE (2013) Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation

- of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation. *Drug Metab Dispos* **41**:2215-2224.
- Bowers GD, Tenero D, Patel P, Huynh P, Sigafos J, O'Mara K, Young GC, Dumont E, Cunningham E, Kurtinecz M, Stump P, Conde JJ, Chism JP, Reese MJ, Yueh YL, and Tomayko JF (2013) Disposition and metabolism of GSK2251052 in humans: a novel boron-containing antibiotic. *Drug Metab Dispos* **41**:1070-1081.
- Dingemans J, Hoever P, Hoch M, Treiber A, Wagner-Redeker W, Miraval T, Hopfgartner G, and Shakeri-Nejad K (2013) Elucidation of the metabolic pathways and the resulting multiple metabolites of almorexant, a dual orexin receptor antagonist, in humans. *Drug Metab Dispos* **41**:1046-1059.
- Harrell AW, Siederer SK, Bal J, Patel NH, Young GC, Felgate CC, Pearce SJ, Roberts AD, Beaumont C, Emmons AJ, Pereira AI, and Kempford RD (2013) Metabolism and disposition of vilanterol, a long-acting $\beta(2)$ -adrenoceptor agonist for inhalation use in humans. *Drug Metab Dispos* **41**:89-100.
- Miao Z, Nucci G, Amin N, Sharma R, Mascitti V, Tugnait M, Vaz AD, Callegari E, and Kalgutkar AS (2013) Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. *Drug Metab Dispos* **41**:445-456.
- Walles M, Wolf T, Jin Y, Ritzau M, Leuthold LA, Krauser J, Gschwind HP, Carcache D, Kittelmann M, Ocwieja M, Ufer M, Woessner R, Chakraborty A, and Swart P (2013) Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects. *Drug Metab Dispos* **41**:1626-1641.

2014

- Dave M, Nash M, Young GC, Ellens H, Magee MH, Roberts AD, Taylor MA, Greenhill RW, and Boyle GW (2014) Disposition and metabolism of darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in humans. *Drug Metab Dispos* **42**:415-430.
- Dowty ME, Lin J, Ryder TF, Wang W, Walker GS, Vaz A, Chan GL, Krishnaswami S, and Prakash C (2014) The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. *Drug Metab Dispos* **42**:759-773.
- Kassahun K, McIntosh I, Koeplinger K, Sun L, Talaty JE, Miller DL, Dixon R, Zajic S, and Stoch SA (2014) Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans. *Drug Metab Dispos* **42**:818-827.
- Mamaril-Fishman D, Zhu J, Lin M, Felgate C, Jones L, Stump P, Pierre E, Bowen C, Naderer O, Dumont E, Patel P, Gorycki PD, Wen B, Chen L, and Deng Y (2014) Investigation of metabolism and disposition of GSK1322322, a peptidase deformylase inhibitor, in healthy humans using the entero-test for biliary sampling. *Drug Metab Dispos* **42**:1314-1325.
- Mamidi RN, Cuyckens F, Chen J, Scheers E, Kalamaridis D, Lin R, Silva J, Sha S, Evans DC, Kelley MF, Devineni D, Johnson MD, and Lim HK (2014) Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans. *Drug Metab Dispos* **42**:903-916.
- Ong V, Flanagan S, Fang E, Dreskin HJ, Locke JB, Bartizal K, and Prokocimer P (2014) Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate. *Drug Metab Dispos* **42**:1275-1284.

- Smith BJ, Pithavala Y, Bu HZ, Kang P, Hee B, Deese AJ, Pool WF, Klamerus KJ, Wu EY, and Dalvie DK (2014) Pharmacokinetics, metabolism, and excretion of [¹⁴C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans. *Drug Metab Dispos* **42**:918-931.
- Tse S, Leung L, Raje S, Seymour M, Shishikura Y, and Obach RS (2014) Disposition and metabolic profiling of [(14)C]cerlapirdine using accelerator mass spectrometry. *Drug Metab Dispos* **42**:2023-2032.
- Vishwanathan K, Mair S, Gupta A, Atherton J, Clarkson-Jones J, Edeki T, and Das S (2014) Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potential. *Drug Metab Dispos* **42**:932-942.

2015

- Lacy S, Hsu B, Miles D, Aftab D, Wang R, and Nguyen L (2015) Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites. *Drug Metab Dispos* **43**:1190-1207.
- Scheers E, Leclercq L, de Jong J, Bode N, Bockx M, Laenen A, Cuyckens F, Skee D, Murphy J, Sukbuntherng J, and Mannens G (2015) Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. *Drug Metab Dispos* **43**:289-297.

2016

- Dickinson PA, Cantarini MV, Collier J, Frewer P, Martin S, Pickup K, and Ballard P (2016) Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor. *Drug Metab Dispos* **44**:1201-1212.
- Huskey SE, Zhu CQ, Fredenhagen A, Kühnöl J, Luneau A, Jian Z, Yang Z, Miao Z, Yang F, Jain JP, Sunkara G, Mangold JB, and Stein DS (2016) KAE609 (Cipargamin), a New Spiroindolone Agent for the Treatment of Malaria: Evaluation of the Absorption, Distribution, Metabolism, and Excretion of a Single Oral 300-mg Dose of [¹⁴C]KAE609 in Healthy Male Subjects. *Drug Metab Dispos* **44**:672-682.
- Shen J, Serby M, Reed A, Lee AJ, Menon R, Zhang X, Marsh K, Wan X, Kavetskaia O, and Fischer V (2016a) Metabolism and Disposition of Hepatitis C Polymerase Inhibitor Dasabuvir in Humans. *Drug Metab Dispos* **44**:1139-1147.
- Shen J, Serby M, Reed A, Lee AJ, Zhang X, Marsh K, Khatri A, Menon R, Kavetskaia O, and Fischer V (2016b) Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans. *Drug Metab Dispos* **44**:1164-1173.
- Shen J, Serby M, Surber B, Lee AJ, Ma J, Badri P, Menon R, Kavetskaia O, de Morais SM, Sydor J, and Fischer V (2016c) Metabolism and Disposition of Pan-Genotypic Inhibitor of Hepatitis C Virus NS5A Ombitasvir in Humans. *Drug Metab Dispos* **44**:1148-1157.
- Takahashi RH, Choo EF, Ma S, Wong S, Halladay J, Deng Y, Rooney I, Gates M, Hop CE, Khojasteh SC, Dresser MJ, and Musib L (2016) Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [¹⁴C]Cobimetinib, a MEK Inhibitor, in Humans. *Drug Metab Dispos* **44**:28-39.

2017

- He H, Tran P, Gu H, Tedesco V, Zhang J, Lin W, Gatlik E, Klein K, and Heimbach T (2017) Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug. *Drug Metab Dispos* **45**:540-555.
- James AD, Marvalin C, Luneau A, Meissner A, and Camenisch G (2017) Comparison of (19)F NMR and (14)C Measurements for the Assessment of ADME of BYL719 (Alpelisib) in Humans. *Drug Metab Dispos* **45**:900-907.
- Jensen KG, Jacobsen AM, Bundgaard C, Nilausen D, Thale Z, Chandrasena G, and Jørgensen M (2017) Lack of Exposure in a First-in-Man Study Due to Aldehyde Oxidase Metabolism: Investigated by Use of 14C-microdose, Humanized Mice, Monkey Pharmacokinetics, and In Vitro Methods. *Drug Metab Dispos* **45**:68-75.
- Liu H, Michmerhuizen MJ, Lao Y, Wan K, Salem AH, Sawicki J, Serby M, Vaidyanathan S, Wong SL, Agarwal S, Dunbar M, Sydor J, de Moraes SM, and Lee AJ (2017) Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites. *Drug Metab Dispos* **45**:294-305.
- Pearson D, Weiss HM, Jin Y, Jaap van Lier J, Erpenbeck VJ, Glaenzel U, End P, Woessner R, Eggimann F, and Camenisch G (2017) Absorption, Distribution, Metabolism, and Excretion of the Oral Prostaglandin D2 Receptor 2 Antagonist Fevipiprant (QAW039) in Healthy Volunteers and In Vitro. *Drug Metab Dispos* **45**:817-825.
- Scheible H, Kraetzer F, Marx A, Johne A, and Wimmer E (2017) Metabolism of the MEK1/2 Inhibitor Pimasertib Involves a Novel Conjugation with Phosphoethanolamine in Patients with Solid Tumors. *Drug Metab Dispos* **45**:174-182.

2018

- Gerisch M, Heinig R, Engelen A, Lang D, Kolkhof P, Radtke M, Platzek J, Lovis K, Rohde G, and Schwarz T (2018) Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro. *Drug Metab Dispos* **46**:1546-1555.
- Glaenzel U, Jin Y, Nufer R, Li W, Schroer K, Adam-Stitah S, Peter van Marle S, Legangneux E, Borell H, James AD, Meissner A, Camenisch G, and Gardin A (2018) Metabolism and Disposition of Siponimod, a Novel Selective S1P(1)/S1P(5) Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism. *Drug Metab Dispos* **46**:1001-1013.
- Gong J, Hansen L, and Iacono L (2018) Clinical Pharmacokinetics and the Impact of Genetic Polymorphism on a CYP2C19 Substrate, BMS-823778, in Healthy Subjects. *Drug Metab Dispos* **46**:316-325.
- Lee CA, Yang C, Shah V, Shen Z, Wilson DM, Ostertag TM, Girardet JL, Hall J, and Gillen M (2018) Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans. *Drug Metab Dispos* **46**:532-541.
- Zheng J, Xin Y, Zhang J, Subramanian R, Murray BP, Whitney JA, Warr MR, Ling J, Moorehead L, Kwan E, Hemenway J, Smith BJ, and Silverman JA (2018) Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite-Resolution for Clinical Development. *Drug Metab Dispos* **46**:237-247.

2019

- de Vries R, Jacobs F, Mannens G, Snoeys J, Cuyckens F, Chien C, and Ward P (2019) Apalutamide Absorption, Metabolism, and Excretion in Healthy Men, and Enzyme Reaction in Human Hepatocytes. *Drug Metab Dispos* **47**:453-464.
- Harrell AW, Wilson R, Man YL, Riddell K, Jarvis E, Young G, Chambers R, Crossman L, Georgiou A, Pereira A, Kenworthy D, Beaumont C, Marotti M, Wilkes D, Hessel EM, and Fahy WA (2019) An Innovative Approach to Characterize Clinical ADME and Pharmacokinetics of the Inhaled Drug Nemiralisib Using an Intravenous Microtracer Combined with an Inhaled Dose and an Oral Radiolabel Dose in Healthy Male Subjects. *Drug Metab Dispos* **47**:1457-1468.
- Podoll T, Pearson PG, Evarts J, Ingallinera T, Bibikova E, Sun H, Gohdes M, Cardinal K, Sanghvi M, and Slatter JG (2019) Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans. *Drug Metab Dispos* **47**:145-154.
- Yamada M, Mendell J, Takakusa H, Shimizu T, and Ando O (2019) Pharmacokinetics, Metabolism, and Excretion of [(14)C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans. *Drug Metab Dispos* **47**:340-349.

2020

- Bourdet DL, Yeola S, Hegde SS, Colson PJ, Barnes CN, and Borin MT (2020) Revefenacin Absorption, Metabolism, and Excretion in Healthy Subjects and Pharmacological Activity of Its Major Metabolite. *Drug Metab Dispos* **48**:1312-1320.
- Clémence C, Fouqueray P, and Sébastien B (2020) In Vitro Investigation, Pharmacokinetics, and Disposition of Imeglimin, a Novel Oral Antidiabetic Drug, in Preclinical Species and Humans. *Drug Metab Dispos* **48**:1330-1346.
- Glaenzel U, Jin Y, Hansen R, Schroer K, Rahmanzadeh G, Pfaar U, Jaap van Lier J, Borell H, Meissner A, Camenisch G, and Zhao S (2020) Absorption, Distribution, Metabolism, and Excretion of Capmatinib (INC280) in Healthy Male Volunteers and In Vitro Aldehyde Oxidase Phenotyping of the Major Metabolite. *Drug Metab Dispos* **48**:873-885.
- Katyayan K, Yi P, Monk S, and Cassidy K (2020) Excretion, Mass Balance, and Metabolism of [(14)C]LY3202626 in Humans: An Interplay of Microbial Reduction, Reabsorption, and Aldehyde Oxidase Oxidation That Leads to an Extended Excretion Profile. *Drug Metab Dispos* **48**:698-707.
- Kong R, Ma J, Hwang S, Goodwin E, Northcutt V, Babiak J, Almstead N, and McIntosh J (2020) Metabolism and Disposition of Ataluren after Oral Administration to Mice, Rats, Dogs, and Humans. *Drug Metab Dispos* **48**:317-325.
- Pusalkar S, Zhou X, Li Y, Cohen L, Yang JJ, Balani SK, Xia C, Shyu WC, Lu C, Venkatakrishnan K, and Chowdhury SK (2020) Biotransformation Pathways and Metabolite Profiles of Oral [(14)C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors. *Drug Metab Dispos* **48**:217-229.

2021

- Surapaneni S, Yerramilli U, Bai A, Dalvie D, Brooks J, Wang X, Selkirk JV, Yan YG, Zhang P, Hargreaves R, Kumar G, Palmisano M, and Tran JQ (2021) Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator. *Drug Metab Dispos* **49**:405-419.

- Taavitsainen P, Prien O, Kähkönen M, Niehues M, Korjamo T, Denner K, Nykänen P, Vuorela A, Jungmann NA, von Bühler CJ, Koskinen M, Zurth C, and Gieschen H (2021) Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans. *Drug Metab Dispos* **49**:420-433.
- Trivedi A, Wahlstrom J, Mackowski M, Dutta S, and Lee E (2021) Pharmacokinetics, Disposition, and Biotransformation of [(14)C]Omeamtiv Mecarbil in Healthy Male Subjects after a Single Intravenous or Oral Dose. *Drug Metab Dispos* **49**:619-628.
- Ueno T, Ishida T, Aluri J, Suzuki M, Beuckmann CT, Kameyama T, Asakura S, and Kusano K (2021) Disposition and Metabolism of [(14)C]Lemborexant in Healthy Human Subjects and Characterization of Its Circulating Metabolites. *Drug Metab Dispos* **49**:31-38.
- Wang-Lakshman L, Miao Z, Wang L, Gu H, Kagan M, Gu J, McNamara E, Walles M, Woessner R, Camenisch G, Einolf HJ, and Chen J (2021) Evaluation of the Absorption, Metabolism, and Excretion of a Single Oral 1-mg Dose of Tropicexor in Healthy Male Subjects and the Concentration Dependence of Tropicexor Metabolism. *Drug Metab Dispos* **49**:548-562.
- Zamek-Gliszczynski MJ, Kenworthy D, Bershas DA, Sanghvi M, Pereira AI, Mudunuru J, Crossman L, Pirhalla JL, Thorpe KM, Dennison J, McLaughlin MM, Allinder M, Swift B, O'Connor-Semmes RL, and Young GC (2021) Pharmacokinetics and ADME Characterization of Intravenous and Oral [(14)C]-Linerixibat in Healthy Male Volunteers. *Drug Metab Dispos* **49**:1109-1117.

2022

- Aviles P, Altares R, van Andel L, Lubomirov R, Fudio S, Rosing H, Márquez Del Pino FM, Tibben MM, Benedic G, Nan-Offeringa L, Estefan XEL, Francesch A, Zeaiter A, Cuevas C, Schellens JHM, and Beijnen JH (2022) Metabolic Disposition of Lurbectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients. *Drug Metab Dispos* **50**:327-340.
- Bauman JN, Doran AC, King-Ahmad A, Sharma R, Walker GS, Lin J, Lin TH, Telliez JB, Tripathy S, Goosen TC, Banfield C, Malhotra BK, and Dowty ME (2022) The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans. *Drug Metab Dispos* **50**:1106-1118.
- Bolledula J, Chen H, Cohen L, Zhou X, Pusalkar S, Berger A, Sedarati F, Venkatakrishnan K, and Chowdhury SK (2022) Metabolism and Disposition of [(14)C]Pevonedistat, a First-in-Class NEDD8-Activating Enzyme Inhibitor, after Intravenous Infusion to Patients with Advanced Solid Tumors. *Drug Metab Dispos* **50**:989-997.
- Holmberg AA, Weidolf L, Necander S, Bold P, Sidhu S, Pelay-Gimeno M, de Ligt RAF, Verheij ER, Jauhainen A, Psallidas I, Wählby Hamrén U, and Prothon S (2022) Characterization of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of Velsecorat Using an Intravenous Microtracer Combined with an Inhaled Dose in Healthy Subjects. *Drug Metab Dispos* **50**:150-157.
- Wen B, Zhang Y, Young GC, Kenworthy D, Pereira A, Pirhalla J, Doyle J, Jordon B, Zhan J, and Johnson M (2022) Investigation of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of the HIV-1 Maturation Inhibitor GSK3640254 Using an Intravenous Microtracer Combined with EnteroTracker for Biliary Sampling. *Drug Metab Dispos* **50**:1442-1453.

Zheng Y, Zhang H, Liu M, Li G, Ma S, Zhang Z, Lin H, Zhan Y, Chen Z, Zhong D, Miao L, and Diao X (2022) Pharmacokinetics, Mass Balance, and Metabolism of the Novel Urate Transporter 1 Inhibitor [(14)C]HR011303 in Humans: Metabolism Is Mediated Predominantly by UDP-Glucuronosyltransferase. *Drug Metab Dispos* **50**:798-808.